Inflammatory mediators and metalloproteinases are altered in acute ischemic stroke (AIS) and play a detrimental effect on clinical severity and hemorrhagic transformation of the ischemic brain lesion. Using data from the Italian multicenter observational MAGIC (MArker bioloGici nell'Ictus Cerebrale) Study, we evaluated the effect of inflammatory and metalloproteinases profiles on three-month functional outcome, hemorrhagic transformation and mortality in 327 patients with AIS treated with intravenous thrombolys in according to SITS-MOST (Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy) criteria. Circulating biomarkers were assessed at baseline and 24 h after thrombolysis. Adjusting for age, sex, baseline glycemia and National Institute of Health Stroke Scale, history of atrial fibrillation or congestive heart failure, and of inflammatory diseases or infections, baseline alpha-2macroglobulin (A2M), baseline serum amyloid protein (SAP) and pre-post tissue-plasminogen activator (tPA) variations (Á) of metalloproteinase 9, remained significantly and independently associated with three-month death [OR (95% CI):A2M:2.99 (1.19-7.53); SAP:5.46 (1.64-18.74); Ámetalloproteinase 9:1.60 (1.12-2.27)]. The addition of baseline A2M and Ámetalloproteinase 9 or baseline SAP and Ámetalloproteinase 9 (model-2 or model-3) to clinical variables (model-1) significantly improved the /home/jcbfm area under curve for prediction of death [model-2 with A2M: p ¼ 0.0205; model-3 with SAP: p ¼ 0.001]. In conclusion, among AIS patients treated with thrombolysis, circulating A2M, SAP and Ámetalloproteinase 9 are independent markers of poor outcome. These results may prompt controlled clinical research about agents antagonizing their effect.
Introduction
Accumulating evidence suggests that inflammatory mechanisms are consistently involved in acute ischemic stroke (IS), and that high levels of inflammatory molecules are associated with early or late neurological deterioration. [1] [2] [3] [4] [5] Post-stroke neuro-inflammatory mechanisms are complex cascade phenomena: after the ischemic insult, changes occurring in the different elements of the neurovascular unit and the subsequent release of pro-inflammatory cytokines stimulates the local production of metalloproteinase (MMP) 9 by both resident cells and infiltrating monocytes and neutrophils. [6] [7] [8] MMP9 contributes to the degradation of neurovascular matrix and the disruption of the tight junction proteins and the cerebrovascular basal lamina protein, further promoting brain injury and favoring, over hours or even days after the initial ischemic event, new leukocyte extravasation, brain edema, and haemorrhagic transformation. 9, 10 Data about such changes occurring in the clinical setting and studied using circulating biomarkers are still scanty and incomplete.
A growing body of studies is confirming the association between a systemic marker of inflammation, i.e. C-reactive protein (CRP), and evolution of ischemic stroke. In fact, elevations of CRP within 24 to 72 h of admission has been consistently shown to be a valuable independent predictor of poor outcomes, even after adjusting for infection and atherosclerosis. 5, 11, 12 Regarding biomarkers associated with poor prognosis in the setting of stroke patients treated with thrombolysis, evidence exists for few factors only. One is definitely blood glucose: in fact hyperglycemia predicts poor outcome not only among untreated patients but also after thrombolytic treatment, as reviewed recently by Hasan et al. 4 A study, recently published by our group, has shown that MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death at three months of follow-up. 13 Concerning CRP and other inflammatory markers of ischemic brain lesion after thrombolysis, scarce and contrasting data are available in literature. [14] [15] [16] No study has addressed hitherto the issue of their potential interaction with MMPs changes.
Using the patients enrolled into MAGIC Study, 13 we sought to investigate the association of pre-and postthrombolysis levels of an extensive array of multiple pro-inflammatory and anti-inflammatory molecules with symptomatic intracerebral hemorrhage (sICH), three-month death and three-month modified Rankin Scale score (mRS). We also studied the interplay between MMPs, tissue inhibitors of metalloproteinase (TIMPs) and the inflammatory markers.
Material and methods

Study population
Eligible were patients admitted for thrombolysis in 14 Italian centers, registered in the Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR), according to SITS-Monitoring Study criteria. 17 Study protocol was approved by local Ethical Committee of the Careggi University Hospital (Florence) and all patients gave informed consent.
The study compliance with the Declaration of Helsinki.
Laboratory determinations
Whole venous blood was collected in tubes without anticoagulant, before and 24 h after thrombolysis. Tubes were centrifuged at room temperature at 1500 g for 15 min, and the supernatants were stored in aliquots at À80 C until measurement of inflammatory markers, MMPs and TIMPs. Samples were analyzed in a unique central laboratory. Levels of different inflammatory markers [interleukin (IL) 1b, IL1RA, IL4, IL6, IL8, IL10, IL12, IL17, interferon gamma (IFNg), IFNginduced protein 10 (IP10), monocyte chemo-attractant protein 1 (MCP1), macrophage inflammatory protein 1 beta (MIP1b), tumor necrosis factor alpha (TNFa), CRP, alpha2 macroglobulin (A2M), serum amyloid P(SAP), and haptoglobin] were determined using Bio-Plex suspension array system and Biorad Kits (Bio-Rad Laboratories Inc., Hercules, CA, USA). MMPs (MMP1, MMP2, MMP3, MMP7, MMP8, and MMP9) and TIMPs (TIMP1, TIMP2, and TIMP4) were previously determined in the same patients 13 using Bio-Plex suspension array system (Bio-Rad Laboratories Inc., Hercules, CA, USA) and R&D Kits (R&D System, Milan Italy) following manufacturer's instructions. The coefficient of variation of inflammatory markers, MMPs and TIMPs assays was <6%.
Outcomes
Outcomes were defined as follows: (1) sICH, using the National Institute of Neurological Disorders and Stroke criteria; 18 (2) three-month death; (3) modified Rankin disability score (mRS), dichotomized into good (mRS, 0-2) or poor (mRS, 3-6) outcome.
Statistical analysis
As a main explanatory variable, we used both baseline and single patient's relative pre-and post-thrombolysis variation (Á median value) of inflammatory markers, MMPs and TIMPs levels. Pre-post thrombolysis variation was calculated according to the formula: [(24-h post-tPA inflammatory markers, MMPs or TIMPs)-(pre-tPA inflammatory markers, MMPs or TIMPs)/ (pre-tPA inflammatory markers, MMPs or TIMPs)]. Differences in these Á values were analyzed in relation to demographic and clinical features and across subgroups of patients with different outcomes.
We used Pearson 2 to test for significance while comparing binary variables and ANOVA or Kruskal-Wallis H Test for numeric variables as appropriate. Values are presented as mean and standard deviation or as median and interquartile range if they had a non-Gaussian distribution.
As the parameters investigated had a non-Gaussian distribution, log-transformed pre-tPA values for cytochemokines, CRP, haptoglobin, SAP and A2M and cube root-transformed pre-post tPA variations were used.
To analyze differences in biomarkers levels between baseline and 24 h, we choose the Mann-Whitney U Test because of relatively large statistical variations. The net effect of each biomarker's baseline or variation on outcomes was then estimated by a logistic regression model including as covariates age, sex, baseline blood glucose, baseline NIHSS, history of atrial fibrillation, history of congestive heart failure, time onset-totreatment, and history of inflammatory disorders or infections, occurred in the last seven days, as the main known outcome determinants. Since there were significant variations in the concentration of studied biomarkers across collaborating centers, in the multivariate analysis we controlled also for center effect. To correct results for multiple comparisons, we used the false discovery rate testing in all the statistical analyses. Furthermore, Spearman correlation test was used to study correlations between each MMP, TIMP and inflammatory marker. Area under the receiver operating characteristic curve (AUC) of different regression models for the detection of bad outcomes was also used.
To quantify how much the addition of a new biomarker correctly increases (upwards movements) or decreases (downwards movements) the risk predicted by the model for events and non-events, we assessed category-free net reclassification improvement (NRI) according to Xanthakis et al. 19 To perform NRI calculation, we categorized the continuous variables A2M and SAP into quartiles (A2M:1 st quartile <1.28 mg/mL, 2 nd quartile 1.28-1.88 mg/mL, 3 rd quartile 1.89-2.67 mg/mL, 4 th quartile >2.67 mg/mL; SAP 1 st quartile <41.5 mg/mL, 2 nd quartile 41.5-54.5, 3 rd quartile 54.6-70.4, 4 th quartile >70.4.
A significant level was defined as P < 0.05. Integrated discrimination improvement (IDI) analysis was also performed. All analyses were performed with SPSS 20.0 (SPSS Inc, Chicago, Ill) and Stata 13.0 (Lakeway Dr College Station, TX).
Results
We investigated 327 IS patients treated with tPA thrombolysis, enrolled between October 2008 and June 2011 (mean age, 68.9 AE 12.1 years; 58% males). The percentage of patients treated with endovascular procedures after tPA was less than 2% overall. A detailed description of patient cohort is reported in our previous paper. 13 Clinical and demographic characteristics are summarized in Table 1 .
Pre-, post-thrombolysis levels and pre-/post-thrombolysis variations of inflammatory markers according to the main outcomes are reported in the on-line-only Data Supplement (see Tables 1, 2 
Correlation between inflammatory markers and MMPs, TIMPs
Baseline A2M significantly correlated with baseline
Baseline SAP levels were also significantly related with baseline MMP3 (r ¼ 0.156), MMP7 (r ¼ 0.160) and MMP8 (r ¼ 0.111), (p < 0.05). The other inflammatory markers were not significantly correlated with TIMPs or MMPs (data not shown).
Logistic regression analyses
At multivariate logistic regression analyses, after adjusting for clinical and demographic determinants of unfavorable outcome, patients with high pre-tPA levels of A2M and SAP ( Table 2 ) and patients with higher variation in A2M, IL1Ra, IL8, IL10, and TNFa had significantly higher risk of death (Table 3) .
Among the inflammatory markers, only CRP, IL1b, IL1Ra, IL6, IL8 and IL10 variations were associated with three-month mRS 3-6 ( Table 3) .
None of the pre-tPA inflammatory markers was significantly related with hemorrhagic transformation (Tables 2). Only pre-post-tPA variation of IL10 was a significant predictor of the hemorrhagic transformation (Table 3) . When in the logistic regression model containing as independent variables age, sex, glycemia, baseline NIHSS, history of atrial fibrillation, or congestive heart failure, history of inflammatory diseases or infections occurred within the last seven days before stroke onset, the inflammatory markers (each one at a time), we added ÁMMP9 or ÁTIMP1 only pre-tPA A2M, SAP and ÁMMP9 remained significantly and independently associated with three-month death [OR (95% CI): baseline A2M: 2.99 (1.19-7.53), p ¼ 0.020; baseline SAP: 5.46 (1.64-18.74); p < 0.01; ÁMMP9: Changes in the risk of death estimated by the model were also significant when SAP was added to the model with traditional risk factors and ÁMMP9 (NRI ¼ 0.493 AE 0.198; p ¼ 0.0126).
The IDI for pre-tPA SAP was 0.0467 AE 0.0187, p ¼ 0.0307, whereas for A2M was not significant (IDI ¼ 00118 AE 0185, p ¼ 0.2617).
No statistical interaction was found between inflammatory markers and MMPs/TIMPs.
Discussion
In this large series of patients treated with i.v. thrombolysis we found that: (1)baseline A2M and SAP levels independently predict three-month death, (2)pre-post tPA variations of CRP, IL1b, and IL6 are associated with worse clinical outcome, (3)pre-tPA values of any of the tested inflammatory markers are related with SICH, whereas only pre-post tPA variation of IL-10 was a significant predictor of hemorrhagic transformation and (4)after adjustment for several potential confounders and MMP9 and TIMP1, only baseline A2M, baseline SAP and ÁMMP9 (reported in our previous study on the same series of patients) remain significantly and independently associated with three-month death.
Inflammation is increasingly recognized to be the key element in pathological progression of IS. After cerebral ischemia, an inflammatory response mediated by the activation of nuclear factor Kappa-B occurs, and cytokines production by microglia and neurons may significantly increase. 20 A recent review of clinical studies aimed to assess biomarkers related to poor stroke outcomes showed that none of the inflammatory molecules are associated with death risk. 4 By using an extensive array of circulating cytokines and other inflammatory markers, we identified, for the first time, A2M and SAP as factors selectively associated with three-month death.
Human A2M is a broad-spectrum proteinase inhibitor, and a cargo protein for growth factors and cytokines in the blood and other extracellular spaces. 21 A2M enhances prothrombotic properties by neutralizing plasmin, plasminogen activators and activated protein C. [22] [23] [24] and acts as proteinase inhibitor through steric shielding and rapid clearance of the bound proteinases. This binding causes change in A2M conformation to an activated form, which recognizes the low-density lipoprotein receptor-related protein 1 (LRP1). 25 In a case-control study, 26 A2M levels were significantly higher in patients with acute IS (especially those with lacunar stroke) than in controls and they were associated with older age and white matter lesion severity. 30 Interestingly, in our study, we found significant correlations between A2M and age (r ¼ 0.27, p < 0.001), and between A2M and NIHSS score at admission (r ¼ 0.21, p < 0.001). In addition, A2M levels turned out to be independently associated with the total anterior circulation syndrome (TACS) (p ¼ 0.034).
SAP is a member of pentraxin family and plays a key role in innate immunity and inflammation. SAP activates the classical complement pathway, has opsonin activity and is a component of extracellular matrices, and is present in elastic fibers in blood vessels. 27, 28 In our study, pre-post tPA variations of CRP, IL1b and IL6 were associated with it three-month mRS 3-6, after adjusting for potential confounders.
In humans, peripheral white blood cell count, CRP level and cytokines are increased within 24 h after the onset of stroke, 7 and a prolonged activity of the postischemic inflammatory response even three months after the onset of stroke 29 was demonstrated. Our data showed that the patients with higher prepost tPA increase in CRP, IL1b, IL6 and SAP were those patients with higher risk of poor outcome (mRS 3-6), confirming the role of CRP in influencing the risk of poor outcome in IS and extend to other inflammatory markers such as IL1b and IL6.
Inflammation may underpin multiple factors known to contribute to the hemorrhagic transformation after thrombolysis such as vascular injury, reperfusion and altered permeability. However, in our study, we did not found any significant association between inflammatory markers and hemorrhagic transformation.
Our data on pre-and post-tPA CRP are consistent with those obtained by Karlinski et al., 16 showing that patients treated with thrombolysis and with high 24 h-serum CRP experienced more frequently sICH than patients with normal CRP level, but after the adjustment for clinical predictors of hemorrhagic transformation, this association did not remain, as in the present study. An unexpected result of our study was the significant association between pre-post tPA variations of IL10 and sICH: patients who experienced the hemorrhagic transformation had higher pre-post tPA variations of the anti-inflammatory cytokine IL-10, suggesting that in these patients, the increased pro-inflammatory response observed after tPA administration was counterbalanced by a higher anti-inflammatory response.
Among different definitions available for ICH occurring after thrombolysis, we choose NINDS criteria as the most sensitive one. In our cohort, the number of patients with symptomatic ICH defined using NINDS criteria was 8.3%, whereas it was 3.7% using ECASS criteria, and only 0.3% using SITS-MOST criteria. The choice of NINDS criteria might affect the results of our study as a recent paper evidenced that the NINDS criteria had the lowest clinical/functional effect. 31 However, in our study, functional outcome was anyhow determined since we had the three months Rankin's score assessed and analyzed for all patients.
In analyzing the interplay between MMPs and the inflammatory markers in determining poor outcomes, we demonstrated that ÁMMP9, baseline A2M and SAP are the only factors independently associated with three-month death, suggesting that both A2M, SAP and MMP9 contributed to the cerebral damage after IS and thrombolysis. A2M, in fact, determines a reduction in the fibrinolytic potential. Furthermore, A2M and LRP1 can regulate matrix MMP, 30 and A2M could be crucial in the progression of atherosclerotic lesions through interaction with LRP1.
The results of our study evidenced that A2M and SAP may be clinically useful as they significantly and correctly increases the risk predicted by the model including traditional risk factors and ÁMMP-9 for death, suggesting that high pre-tPA levels of A2M and SAP may be useful to identify those patients with and increase probability of death after the administration of tPA.
From a translational, clinical practice point of view, the determination of pre-tPA levels of A2M and SAP, easily and quickly assessed by immune-nephelometric assay already available in general laboratories, could help identifying very early, i.e. soon after the treatment, patients at higher risk of worse outcome to be eventually subjected to a more intensive surveillance and care.
Further studies are needed to confirm the role of biomarkers also in ischemic stroke patients treated with endovascular thrombectomy.
The specific role of rtPA in stroke-related inflammation remains largely unknown since most of the side effects could be due to reperfusion injury itself. Recent experimental data show an effect on rtPA in enhancing microglia cell recruitment after transient middle cerebral artery occlusion (MCAO) in mice. 32 In another study, protein levels of IL6, TNF alpha, MMP9 were attenuated after MCAO in those animals where the thrombolysis was successful. 33 One limitation of our study is the lack of a control group of patients with stroke not treated with tPA. A further limitation rests upon the lack of further blood sampling to determine the inflammatory response during the first days after stroke, as different time-courses are characteristic feature of different inflammatory markers.
In conclusion, our study documented that inflammation and particularly A2M and SAP influence, the adverse outcomes in IS patients treated with tPA, and suggests the usefulness of determining pre-tPA A2M and SAP as surrogate predictor of unfavorable stroke outcomes.
By exploring the complex interaction among several inflammatory markers and MMPs, and by using an extensive array of cytokine/chemokines and MMPs, our results provide further insights into the pathophysiological mechanisms underlying the unfavorable outcomes after thrombolysis.
Present findings encourage controlled clinical trials to test the effectiveness of MMP antagonists and antiinflammatory therapy administered together with tPA. 
